We further establish the druggability of the NaV1.7 channel in MTC by identifying a novel inhibitor and investigate its mode of binding and ability to inhibit the Na+ current (INa) in NaV1.7. This evidence concerns the gene SCN9A and medullary thyroid gland carcinoma.